Deciphera Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Deciphera Pharmaceuticals de 41.1% y 21.7% por año respectivamente. Se prevé que el BPA crezca en un 43.2% al año. Se espera que la rentabilidad financiera sea de -55% en 3 años.

Información clave

45.0%

Tasa de crecimiento de los beneficios

46.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.4%
Tasa de crecimiento de los ingresos	21.8%
Rentabilidad financiera futura	-55.0%
Cobertura de analistas	Good
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10

Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Feb 11

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Feb 05

Deciphera to expand geographic reach and clinical potential of ripretinib

Jan 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:DCPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	375	-71	-49	-103	8
12/31/2025	264	-156	-145	-141	9
12/31/2024	202	-196	-176	-147	9
12/31/2023	163	-195	-147	-147	N/A
9/30/2023	151	-194	-154	-153	N/A
6/30/2023	144	-187	-145	-144	N/A
3/31/2023	138	-182	-152	-151	N/A
12/31/2022	134	-179	-154	-153	N/A
9/30/2022	122	-221	-185	-185	N/A
6/30/2022	109	-258	-223	-218	N/A
3/31/2022	100	-286	-230	-224	N/A
12/31/2021	96	-300	-247	-241	N/A
9/30/2021	91	-274	-230	-223	N/A
6/30/2021	84	-258	-221	-218	N/A
3/31/2021	67	-255	-232	-227	N/A
12/31/2020	42	-266	-245	-240	N/A
9/30/2020	23	-271	-253	-246	N/A
6/30/2020	7	-263	-229	-220	N/A
3/31/2020	25	-218	-202	-197	N/A
12/31/2019	25	-192	-154	-149	N/A
9/30/2019	25	-157	-124	-120	N/A
6/30/2019	25	-126	-123	-122	N/A
3/31/2019	N/A	-126	-104	-103	N/A
12/31/2018	N/A	-100	-88	-87	N/A
9/30/2018	N/A	-87	-74	-73	N/A
6/30/2018	N/A	-75	-58	-57	N/A
3/31/2018	N/A	-64	-47	-46	N/A
12/31/2017	N/A	-50	-37	-37	N/A
9/30/2017	N/A	-39	N/A	-31	N/A
6/30/2017	N/A	-33	N/A	-28	N/A
3/31/2017	N/A	-28	N/A	-25	N/A
12/31/2016	N/A	-26	N/A	-23	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que DCPH siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que DCPH siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que DCPH siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.7% al año) de DCPH crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (21.7% al año) de DCPH crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: DCPH se prevé que no sea rentable en 3 años.

Deciphera Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.1% to US$25.38

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Price target increased by 11% to US$24.44

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Recent updates

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Price target decreased to US$59.27

Third quarter 2021 earnings released: US$1.37 loss per share (vs US$1.13 loss in 3Q 2020)

Executive VP & Chief Medical Officer recently sold US$88k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans